Literature DB >> 30173284

Short-Term Impact of Bariatric Surgery on Best-Corrected Distance Visual Acuity and Diabetic Retinopathy Progression.

Patrick Richardson1, Adela Hulpus1, Iskandar Idris2,3,4.   

Abstract

The immediate impact of rapid glucose lowering induced by bariatric surgery on diabetic retinopathy (DR) progression remains unclear. We present 3-year changes in the best-corrected visual acuity and DR grade in a retrospective observational study of 32 morbidly obese patients (64 eyes) who underwent Roux-en-Y-gastric bypass surgery. We found that despite overall benefits in vision, there was an initial progression from no retinopathy to background retinopathy in 18.9% and 21.7% at years 1 and 2 respectively. Patients with pre-proliferative DR at baseline were at increased risk of developing sight-threatening DR. We recommend that patients with diabetes undergoing bariatric surgery have a baseline visual acuity, macular optical coherent tomography and diabetic retinopathy grading from wide-field digital imaging to identify those at risk of sight-threatening diabetic retinopathy.

Entities:  

Keywords:  Diabetes; Retinopathy

Mesh:

Year:  2018        PMID: 30173284     DOI: 10.1007/s11695-018-3445-z

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  9 in total

1.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Authors:  Steven P Marso; Stephen C Bain; Agostino Consoli; Freddy G Eliaschewitz; Esteban Jódar; Lawrence A Leiter; Ildiko Lingvay; Julio Rosenstock; Jochen Seufert; Mark L Warren; Vincent Woo; Oluf Hansen; Anders G Holst; Jonas Pettersson; Tina Vilsbøll
Journal:  N Engl J Med       Date:  2016-09-15       Impact factor: 91.245

2.  Long-term Microvascular Disease Outcomes in Patients With Type 2 Diabetes After Bariatric Surgery: Evidence for the Legacy Effect of Surgery.

Authors:  Karen J Coleman; Sebastien Haneuse; Eric Johnson; Andy Bogart; David Fisher; Patrick J O'Connor; Nancy E Sherwood; Steve Sidney; Mary Kay Theis; Jane Anau; Emily B Schroeder; Rebecca O'Brien; David Arterburn
Journal:  Diabetes Care       Date:  2016-06-06       Impact factor: 19.112

3.  Progression of diabetic retinopathy after bariatric surgery.

Authors:  R Murphy; Y Jiang; M Booth; R Babor; A MacCormick; H Hammodat; G Beban; R M Barnes; A L Vincent
Journal:  Diabet Med       Date:  2015-02-26       Impact factor: 4.359

Review 4.  Bariatric surgery and diabetic retinopathy: a systematic review and meta-analysis of controlled clinical studies.

Authors:  C Merlotti; V Ceriani; A Morabito; A E Pontiroli
Journal:  Obes Rev       Date:  2017-01-13       Impact factor: 9.213

Review 5.  Early worsening of diabetic retinopathy after rapid improvement of blood glucose control in patients with diabetes.

Authors:  S Feldman-Billard; É Larger; P Massin
Journal:  Diabetes Metab       Date:  2017-11-11       Impact factor: 6.041

6.  Early retinopathy progression in four randomized trials comparing insulin glargine and NPH [corrected] insulin.

Authors:  M D Davis; R W Beck; P D Home; J Sandow; F L Ferris
Journal:  Exp Clin Endocrinol Diabetes       Date:  2007-04       Impact factor: 2.949

Review 7.  Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis.

Authors:  Henry Buchwald; Rhonda Estok; Kyle Fahrbach; Deirdre Banel; Michael D Jensen; Walter J Pories; John P Bantle; Isabella Sledge
Journal:  Am J Med       Date:  2009-03       Impact factor: 4.965

8.  Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy.

Authors:  Tina Vilsbøll; Stephen C Bain; Lawrence A Leiter; Ildiko Lingvay; David Matthews; Rafael Simó; Ida Carøe Helmark; Nelun Wijayasinghe; Michael Larsen
Journal:  Diabetes Obes Metab       Date:  2018-01-08       Impact factor: 6.577

9.  Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study.

Authors:  J Rosenstock; V Fonseca; J B McGill; M Riddle; J-P Hallé; I Hramiak; P Johnston; M Davis
Journal:  Diabetologia       Date:  2009-06-13       Impact factor: 10.122

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.